In a phase I trial, the association between the HDAC inhibitor vorinostat and the mTOR inhibitor ridaforolimus showed signals of efficacy in advanced solid tumors, especially ccRCC, despite thrombocytopenia as a significant toxicity [48]. This evidence concerns the gene HDAC9 and nonpapillary renal cell carcinoma.